- RESEARCH HIGHLIGHT
Switching off MDSCs by targeting REL
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 19, 445 (2020)
doi: https://doi.org/10.1038/d41573-020-00103-2
This article originally appeared in Nat. Rev. Cancer (https://doi.org/10.1038/s41568-020-0277-7)
References
Li, T. et al. c-Rel is a myeloid checkpoint for cancer immunotherapy. Nat. Cancer 1, 507–517 (2020)